MX2015014656A - Formulaciones de liberacion prolongada de colchicina y metodos de uso de las mismas. - Google Patents
Formulaciones de liberacion prolongada de colchicina y metodos de uso de las mismas.Info
- Publication number
- MX2015014656A MX2015014656A MX2015014656A MX2015014656A MX2015014656A MX 2015014656 A MX2015014656 A MX 2015014656A MX 2015014656 A MX2015014656 A MX 2015014656A MX 2015014656 A MX2015014656 A MX 2015014656A MX 2015014656 A MX2015014656 A MX 2015014656A
- Authority
- MX
- Mexico
- Prior art keywords
- colchicine
- sustained
- methods
- same
- release
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Ophthalmology & Optometry (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychiatry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Se proveen composiciones farmacéuticas de colchicina para su administración oral una vez al día. Las formulaciones comprenden un componente de liberación prolongada y un componente de liberación inmediata opcional cuyas composiciones pueden ser selectivamente ajustadas, respectivamente, para liberar el ingrediente activo de acuerdo a un perfil de liberación predeterminado o deseado. También se provee un método de tratamiento o prevención de una enfermedad cardiovascular y/o enfermedad inflamatoria en mamíferos que comprende la administración de las nuevas formulaciones descriptas en la presente.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361812514P | 2013-04-16 | 2013-04-16 | |
EP13194505 | 2013-11-26 | ||
PCT/IB2014/001201 WO2014170755A2 (en) | 2013-04-16 | 2014-04-16 | Sustained-release formulations of colchicine and methods of using same |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2015014656A true MX2015014656A (es) | 2016-03-01 |
Family
ID=49683519
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2015014656A MX2015014656A (es) | 2013-04-16 | 2014-04-16 | Formulaciones de liberacion prolongada de colchicina y metodos de uso de las mismas. |
MX2020012310A MX2020012310A (es) | 2013-04-16 | 2015-10-16 | Formulaciones de liberacion prolongada de colchicina y metodos de uso de las mismas. |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020012310A MX2020012310A (es) | 2013-04-16 | 2015-10-16 | Formulaciones de liberacion prolongada de colchicina y metodos de uso de las mismas. |
Country Status (19)
Country | Link |
---|---|
US (6) | US20160081936A1 (es) |
EP (1) | EP2986280B1 (es) |
JP (1) | JP6480420B2 (es) |
KR (1) | KR102271048B1 (es) |
CN (1) | CN105307643A (es) |
AU (4) | AU2014255434B2 (es) |
BR (1) | BR112015026418B1 (es) |
CA (1) | CA2909370A1 (es) |
CL (1) | CL2015003072A1 (es) |
EA (1) | EA037375B1 (es) |
MA (1) | MA38576B2 (es) |
MX (2) | MX2015014656A (es) |
MY (1) | MY198452A (es) |
PL (1) | PL2986280T3 (es) |
PT (1) | PT2986280T (es) |
SG (1) | SG11201508571WA (es) |
SI (1) | SI2986280T1 (es) |
WO (1) | WO2014170755A2 (es) |
ZA (1) | ZA201507723B (es) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112015010063B1 (pt) | 2012-11-02 | 2021-11-09 | Murray And Poole Enterprises, Ltd | Uso de uma composição compreendendo colchicina, um sal de colchicina ou combinação desses |
AU2014255434B2 (en) | 2013-04-16 | 2018-11-08 | Murray And Poole Enterprises Limited | Sustained-release formulations of colchicine and methods of using same |
EP3998066A1 (en) * | 2015-04-17 | 2022-05-18 | Murray And Poole Enterprises Limited | Colchicine salicylate and uses thereof |
US9907751B2 (en) * | 2016-03-10 | 2018-03-06 | RxOMEG Therapeutics LLC | Composition and method of use of colchicine oral liquid |
US11534421B2 (en) * | 2017-06-23 | 2022-12-27 | Nordiccan A/S | Cannabinoid pouch |
US10226423B1 (en) * | 2017-12-20 | 2019-03-12 | RxOMEG Therapeutics LLC | Colchicine drug-to-drug interactions |
JP2022514997A (ja) | 2018-02-02 | 2022-02-17 | マリー アンド プール エンタープライゼズ,リミテッド | 腫瘍の増殖及び転移を阻害するためのコルヒチンの使用 |
CN110448527B (zh) * | 2019-09-23 | 2021-11-26 | 杭州百诚医药科技股份有限公司 | 一种秋水仙碱口服溶液及其处方组成 |
KR102112456B1 (ko) | 2019-11-13 | 2020-05-19 | 주식회사 에이스바이오메드 | 간 질환 치료용 또는 치료 효과 증진을 위한 콜히친 복합제제 |
CN111150702B (zh) * | 2019-12-04 | 2021-06-22 | 复旦大学 | 一种凝胶药物缓释制剂及其制备方法与应用 |
KR102584738B1 (ko) | 2020-01-17 | 2023-10-06 | 한국생명공학연구원 | 콜히친을 포함하는 피부 질환 치료용 조성물 |
KR102150821B1 (ko) | 2020-01-22 | 2020-09-03 | 주식회사 에이스바이오메드 | 간 질환 치료용 또는 치료 효과 증진을 위한 콜히친 복합제제 |
KR20210095249A (ko) | 2020-01-22 | 2021-08-02 | 주식회사 에이스바이오메드 | 간 질환 치료용 또는 치료 효과 증진을 위한 콜히친 복합제제 |
KR102177781B1 (ko) | 2020-04-27 | 2020-11-12 | 주식회사 에이스바이오메드 | 간 질환 치료용 또는 치료 효과 증진을 위한 콜히친, 우르소데옥시콜산 및 비페닐디메틸디카르복실레이트의 복합제제 |
WO2022132786A1 (en) * | 2020-12-15 | 2022-06-23 | Romeg Therapeutics Llc | Methods and compositions for treating pericarditis |
CN113476603B (zh) * | 2021-07-08 | 2022-05-20 | 中南大学 | 一种红细胞膜包裹的磁性纳米颗粒及其制备方法和应用 |
Family Cites Families (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3173876A (en) | 1960-05-27 | 1965-03-16 | John C Zobrist | Cleaning methods and compositions |
US3276586A (en) | 1963-08-30 | 1966-10-04 | Rosaen Filter Co | Indicating means for fluid filters |
US3546142A (en) | 1967-01-19 | 1970-12-08 | Amicon Corp | Polyelectrolyte structures |
US3541006A (en) | 1968-07-03 | 1970-11-17 | Amicon Corp | Ultrafiltration process |
US3541005A (en) | 1969-02-05 | 1970-11-17 | Amicon Corp | Continuous ultrafiltration of macromolecular solutions |
US4285987A (en) | 1978-10-23 | 1981-08-25 | Alza Corporation | Process for manufacturing device with dispersion zone |
SE9003904D0 (sv) * | 1990-12-07 | 1990-12-07 | Astra Ab | Method for the manufacture of a pharmaceutical dosage form |
US5171217A (en) | 1991-02-28 | 1992-12-15 | Indiana University Foundation | Method for delivery of smooth muscle cell inhibitors |
US7820383B2 (en) | 1997-03-10 | 2010-10-26 | Interleukin Genetics, Inc. | Method for diagnosing myocardial infarction |
JP2000034224A (ja) * | 1998-05-11 | 2000-02-02 | Freunt Ind Co Ltd | 徐放性錠剤、その添加剤組成物及びそれらの製造方法 |
US20020169145A1 (en) * | 1998-10-14 | 2002-11-14 | Rajen Shah | Sustained release pharmaceutical composition and method of releasing pharmaceutically active agent |
EP1239856A1 (en) * | 1999-12-22 | 2002-09-18 | Pharmacia Corporation | Sustained-release formulation of a cyclooxygenase-2 inhibitor |
JP2004529902A (ja) | 2001-03-13 | 2004-09-30 | ペンウェスト ファーマシューティカルズ カンパニー | グルココルチコステロイドを含有する時間治療(chronotherapeutic)投与形態 |
US8853266B2 (en) | 2001-12-06 | 2014-10-07 | University Of Tennessee Research Foundation | Selective androgen receptor modulators for treating diabetes |
US20030144203A1 (en) * | 2001-12-19 | 2003-07-31 | Voyager Pharmaceutical Corporation | Methods for slowing senescence and treating and preventing diseases associated with senescence |
SE0401031D0 (sv) * | 2004-04-22 | 2004-04-22 | Duocort Ab | A new glucocorticoid replacement therapy |
US20060045865A1 (en) | 2004-08-27 | 2006-03-02 | Spherics, Inc. | Controlled regional oral delivery |
WO2006063091A2 (en) | 2004-12-06 | 2006-06-15 | Ronald Freudenberger | Use of oxypurinol as an inhibitor of anti-neoplastic agent-induced cardiotoxicity |
US20060171948A1 (en) | 2005-02-02 | 2006-08-03 | Weinstein Steven P | Methods of using IL-1 antagonists to reduce C-reactive protein |
US20060286108A1 (en) | 2005-06-16 | 2006-12-21 | Bell Katherine A | Topical compositions for the treatment of chronic wounds |
CN1748671A (zh) | 2005-08-30 | 2006-03-22 | 孔庆忠 | 含抗有丝分裂药物的缓释注射剂 |
CN1939290A (zh) | 2005-09-29 | 2007-04-04 | 陆宪光 | 秋水仙碱及它的衍生物的医学用途 |
WO2007048004A2 (en) | 2005-10-21 | 2007-04-26 | Cornell Research Foundation, Inc. | Compounds for enhancing hypoxia inducible factor activity and methods of use |
EP2023874A4 (en) | 2006-06-02 | 2009-07-08 | Bioseek Inc | METHOD FOR IDENTIFYING ACTIVE SUBSTANCES AND THEIR USE FOR THE PREVENTION OF RESTENOSIS |
RS51973B (en) * | 2006-06-09 | 2012-02-29 | Ucb Pharma Gmbh. | STABLE PHARMACEUTICAL PRODUCTS CONTAINING FEZOTERODINE |
PT103884A (pt) * | 2006-11-17 | 2008-05-19 | Astrazeneca Ab | Composições de libertação prolongada e métodos para a sua preparação |
WO2008131192A2 (en) | 2007-04-18 | 2008-10-30 | The Trustees Of Columbia University In The City Of New York | Crystalline cholestrol and prevention of atherosclerosis |
US20090093548A1 (en) | 2007-10-05 | 2009-04-09 | Mutual Pharmaceutical Company, Inc | Colchine compositions and methods |
CN101485638A (zh) * | 2008-01-18 | 2009-07-22 | 普尔药物科技开发(深圳)有限公司 | 秋水仙碱双层渗透泵控释片及其制备方法 |
CN101485637B (zh) * | 2008-01-18 | 2011-03-30 | 普尔药物科技开发(深圳)有限公司 | 秋水仙碱骨架控释片或胶囊 |
WO2009097450A1 (en) | 2008-01-30 | 2009-08-06 | Dexcom. Inc. | Continuous cardiac marker sensor system |
CN101536990A (zh) * | 2008-03-18 | 2009-09-23 | 普尔药物科技开发(深圳)有限公司 | 秋水仙碱胃漂浮缓释片及其制备方法 |
WO2009151770A2 (en) | 2008-04-15 | 2009-12-17 | Mutual Pharmaceutical Company, Inc. | Colchicine solid-state forms; methods of making; and methods of use thereof |
DE102008047910A1 (de) * | 2008-09-19 | 2010-03-25 | Molkerei Meggle Wasserburg Gmbh & Co. Kg | Tablettierhilfsstoff auf Laktose- und Cellulosebasis |
GB0819287D0 (en) | 2008-10-22 | 2008-11-26 | Univ Bradford | Compounds |
CN101732274A (zh) * | 2008-11-19 | 2010-06-16 | 普尔药物科技开发(深圳)有限公司 | 秋水仙碱双层缓释片及其制备方法 |
US7820681B1 (en) | 2009-01-14 | 2010-10-26 | Mutual Pharmaceutical Company, Inc. | Methods for concomitant administration of colchicine and a second active agent |
EP2405898A2 (en) * | 2009-03-09 | 2012-01-18 | Council Of Scientific & Industrial Research | Sustained release composition of therapeutic agent |
US20110046228A1 (en) | 2009-08-20 | 2011-02-24 | Mutual Pharmaceutical Company, Inc. | Methods for administration of colchicine with grapefruit juice |
US20110046227A1 (en) | 2009-08-21 | 2011-02-24 | Mutual Pharmaceutical Company, Inc. | Methods for concomitant administration of colchicine and a second active agent |
ES2689107T3 (es) | 2009-11-13 | 2018-11-08 | Astrazeneca Ab | Formulaciones de tabletas bicapa |
EP2481411A1 (en) * | 2011-01-27 | 2012-08-01 | Ratiopharm GmbH | Oral dosage forms for modified release comprising the JAK3 inhibitor tasocitinib |
EA028495B1 (ru) | 2012-04-13 | 2017-11-30 | Саймабэй Терапьютикс, Инк. | Пероральная композиция для лечения подагры на основе (-)-галофената и колхицина |
BR112015010063B1 (pt) | 2012-11-02 | 2021-11-09 | Murray And Poole Enterprises, Ltd | Uso de uma composição compreendendo colchicina, um sal de colchicina ou combinação desses |
AU2014255434B2 (en) * | 2013-04-16 | 2018-11-08 | Murray And Poole Enterprises Limited | Sustained-release formulations of colchicine and methods of using same |
CN110148563A (zh) * | 2019-05-23 | 2019-08-20 | 武汉新芯集成电路制造有限公司 | 一种半导体器件及其制造方法 |
-
2014
- 2014-04-16 AU AU2014255434A patent/AU2014255434B2/en active Active
- 2014-04-16 CA CA2909370A patent/CA2909370A1/en active Pending
- 2014-04-16 SG SG11201508571WA patent/SG11201508571WA/en unknown
- 2014-04-16 MX MX2015014656A patent/MX2015014656A/es active IP Right Grant
- 2014-04-16 JP JP2016508251A patent/JP6480420B2/ja active Active
- 2014-04-16 EP EP14755124.6A patent/EP2986280B1/en active Active
- 2014-04-16 WO PCT/IB2014/001201 patent/WO2014170755A2/en active Application Filing
- 2014-04-16 SI SI201431839T patent/SI2986280T1/sl unknown
- 2014-04-16 US US14/784,596 patent/US20160081936A1/en not_active Abandoned
- 2014-04-16 PT PT147551246T patent/PT2986280T/pt unknown
- 2014-04-16 PL PL14755124T patent/PL2986280T3/pl unknown
- 2014-04-16 KR KR1020157032568A patent/KR102271048B1/ko active IP Right Grant
- 2014-04-16 MA MA38576A patent/MA38576B2/fr unknown
- 2014-04-16 CN CN201480034165.9A patent/CN105307643A/zh active Pending
- 2014-04-16 BR BR112015026418-2A patent/BR112015026418B1/pt active IP Right Grant
- 2014-04-16 EA EA201501024A patent/EA037375B1/ru not_active IP Right Cessation
- 2014-04-16 MY MYPI2015002561A patent/MY198452A/en unknown
- 2014-12-08 US US14/563,537 patent/US10130585B2/en active Active
- 2014-12-08 US US14/563,503 patent/US10105319B2/en active Active
-
2015
- 2015-10-15 ZA ZA2015/07723A patent/ZA201507723B/en unknown
- 2015-10-16 MX MX2020012310A patent/MX2020012310A/es unknown
- 2015-10-16 CL CL2015003072A patent/CL2015003072A1/es unknown
-
2018
- 2018-10-19 US US16/165,696 patent/US10610488B2/en active Active
-
2019
- 2019-02-14 AU AU2019201048A patent/AU2019201048B2/en active Active
- 2019-10-07 US US16/594,543 patent/US11648206B2/en active Active
-
2020
- 2020-12-23 AU AU2020294268A patent/AU2020294268B2/en active Active
-
2023
- 2023-09-12 US US18/367,416 patent/US20230414521A1/en active Pending
-
2024
- 2024-07-29 AU AU2024205185A patent/AU2024205185A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2020012310A (es) | Formulaciones de liberacion prolongada de colchicina y metodos de uso de las mismas. | |
MX2009001711A (es) | Formulaciones de liberacion sostenida de topiramato. | |
MX2023006541A (es) | Formulaciones de dosis fija. | |
MX2018002462A (es) | Una composicion farmaceutica para reducir la grasa localizada y sus usos. | |
SG10201810985XA (en) | Tofacitinib oral sustained release dosage forms | |
MY161593A (en) | Oral formulations of cytidine analogs and methods of use thereof | |
NZ756231A (en) | A novel isoindoline derivative, a pharmaceutical composition and use thereof | |
PH12018501072A1 (en) | Modified release orally administered amino acid formulations | |
TN2015000135A1 (en) | Modified release formulations for oprozomib | |
WO2014107730A3 (en) | Use of fatty acid niacin conjugates for treating diseases | |
BR112017009510A2 (pt) | composições compreendendo ciclosporina | |
MX2018012618A (es) | Composiciones farmaceuticas orales de mesalazina. | |
BR112014020271A8 (pt) | Composição farmacêutica e métodos para diminuir a frequência de micção em paciente | |
PH12015502556A1 (en) | Modified release formulation | |
MX2018000262A (es) | Usos terapeuticos de formulaciones de berberina. | |
MX2017005163A (es) | Composiciones de liberación prolongada de onapristona y métodos. | |
DOP2013000115A (es) | Formulación de un complejo que comprende clorhidrato de lercanidipina y valsartán y método para la preparación de la misma | |
SA516370446B1 (ar) | تركيبة صيدلانية مستقرة مضادة للدرن في صورة قرص قابل للتشتت يحتوي على حبيبات إيزونيازيد وحبيبات ريفابنتين، وعملية لتحضيرها | |
ECSP16005208A (es) | Composición farmacéutica anti-tuberculosis estable en una forma de un comprimido recubierto que comprende gránulos de isoniazid y gránulos de rifapentina y su proceso de preparación | |
MX2019015869A (es) | Nuevas formulaciones orales de belinostat. | |
MX2019005005A (es) | Tableta de liberacion extendida que comprende un farmaco de perdida de peso. | |
TW201613600A (en) | Piperazinyl derivative reduces HFD-induced accumulation of fat in the liver, therapeutically | |
IN2013MU02110A (es) | ||
IN2013MU02111A (es) | ||
CL2013003070A1 (es) | Sales (2e)-3-carboxiacrilato, fosfatodihidrogeno y 2,6-dioxido-1.2,3,6-tetrahidropirimidina-4-carboxilato de 3-carboxi-n-etil-n,n-dimetilpropan-1-amonio; procedimiento de preparacion; y uso en el tratamiento de enfermedades cardiovasculares. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |